A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets
- 17 September 2024
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (9) , e0053524
Abstract
Coronaviruses (CoVs) are important pathogens for humans and other vertebrates, causing severe respiratory and intestinal infections that have become a threat to public health because of the potential for interspecies transmission between animals and humans. Therefore, the development of safe, effective vaccines remains a top priority for the control of CoV infection. The unique immunological characteristics of vaccines featuring messenger RNA (mRNA) present an advantageous tool for coronavirus vaccine development. Here, we designed two lipid nanoparticle (LNP)-encapsulated mRNA (mRNA-LNP) vaccines: one encoding full-length spike (S) protein and the other encoding the spike ectodomain (Se) from porcine deltacoronavirus (PDCoV). Fourteen days after primary immunization, both mRNA vaccines induced high levels of immunoglobulin G and neutralizing antibodies in mice, with the S vaccine showing better performance than the Se vaccine. Passive immune protection of the S mRNA vaccine in suckling piglets was confirmed by the induction of robust PDCoV-specific humoral and cellular immune responses. The S mRNA vaccine also showed better protective effects than the inactivated vaccine. Our results suggest that the novel PDCoV-S mRNA-LNP vaccine may have the potential to combat PDCoV infection. IMPORTANCE: As an emerging porcine enteropathogenic coronavirus, porcine deltacoronavirus (PDCoV) has the potential for cross-species transmission, attracting extensive attention. Messenger RNA (mRNA) vaccines are a promising option for combating emerging and re-emerging infectious diseases, as evidenced by the demonstrated efficacy of the COVID-19 mRNA vaccine. Here, we first demonstrated that PDCoV-S mRNA-lipid nanoparticle (LNP) vaccines could induce potent humoral and cellular immune responses in mice. An evaluation of passive immune protection of S mRNA vaccines in suckling piglets confirmed that the protective effect of mRNA vaccine was better than that of inactivated vaccine. This study suggests that the PDCoV-S mRNA-LNP vaccine may serve as a potential and novel vaccine candidate for combating PDCoV infection.Keywords
This publication has 34 references indexed in Scilit:
- Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in miceVaccine, 2022
- Advances in COVID-19 mRNA vaccine developmentSignal Transduction and Targeted Therapy, 2022
- Pathogenicity, infective dose and altered gut microbiota in piglets infected with porcine deltacoronavirusVirology, 2022
- An overview of biodegradable nanomaterials and applications in vaccinesVaccine, 2020
- Calves are susceptible to infection with the newly emerged porcine deltacoronavirus, but not with the swine enteric alphacoronavirus, porcine epidemic diarrhea virusArchives of Virology, 2017
- Porcine deltacoronavirus: histological lesions and genetic characterizationArchives of Virology, 2015
- NMR structures and localization of the potential fusion peptides and the pre-transmembrane region of SARS-CoV: Implications in membrane fusionBiochimica et Biophysica Acta (BBA) - Biomembranes, 2015
- mRNA-based therapeutics — developing a new class of drugsNature Reviews Drug Discovery, 2014
- Coordinate regulation of mRNA decay networks by GU-rich elements and CELF1Current Opinion in Genetics & Development, 2011
- Immune Responses to the Microbiota at the Intestinal Mucosal SurfaceImmunity, 2009